An apple a day: Could diet be used to manage autoimmune diseases?
Autoimmune diseases are a hallmark of many modern societies, with onset and progression driven by intestinal barrier dysfunction and a breakdown in normal host–microbiome interactions. Existing autoimmune disease therapies do not consider the influence of the gut microbiome in pathogenesis, which could limit their ability to alter disease progression. A collaboration between the Luxembourg Institute of Health (LIH) and the US University of Michigan Medical School, led by Prof Desai of the LIH, has published a comprehensive Perspective, in the prestigious journal Nature Reviews Gastroenterology and Hepatology, that argues that emerging personalised medicine approaches should embrace diet-assisted microbiome engineering tools to precisely remodel the microbiome towards a disease-resistant, homeostatic state.
Luxembourg rewarded for its translational medicine excellence
In August 2021, the Luxembourg node of the European Research Infrastructure for Translational Medicine (EATRIS) network was granted the EATRIS Node Reward Framework award for its significant contribution to the efforts and impact of the European infrastructure in advancing translational medicine in 2020.
LIH scientist at the forefront of European nutritional health
On July 1st 2021, Dr Torsten Bohn from the Nutrition and Health Research Group (DoPH), became part of the European Food Safety Authority (EFSA) panel for Nutrition, Novel Foods and Allergens (NDA). This highly sought-after position makes Dr Bohn one of only 16 external EFSA experts able to advise on Diet and Health decisions for the whole of Europe.
Personalised medicine of obesity: An innovative tool to diagnose visceral fat
A fruitful collaboration between Research and Development teams* of the Luxembourg Institute of Health and the Centre Hospitalier de Luxembourg (CHL) enabled the development of the Visceral Fat Calculator, an online tool providing an accurate and easy evaluation of the visceral fat depots for adults.
[Press release] Advancing the treatment of Parkinson’s disease
The Luxembourg Institute of Health (LIH) and the Centre Hospitalier de Luxembourg (CHL) announce the launch of “SCOL” (Study of Continuous Oral Levodopa), a unique international clinical trial aiming to assess the safety, tolerability and efficacy of the new DopaFuse System for the continuous oral delivery of levodopa to better treat the symptoms of Parkinson’s Disease. The clinical trial, which is being conducted concomitantly in Italy, Spain and Luxembourg, has the potential to revolutionise the treatment of this common neurodegenerative disease by facilitating drug delivery and reducing side effects.
23 September 2021 03:00 PM
WEBINAR: Lecture series Cancer Research: "Myeloid Cells in Glioblastoma" - Prof Dolores Hambardzumyan
16 September 2021 11:00 AM
WEBINAR: Lecture series in Infection & Immunity - "The COVID-19 pandemic and the response by the scientific community in Luxembourg" - Prof Paul Wilmes